
|Articles|July 1, 2004
POINT LAUNCHES STUDY
Point Therapeutics Inc. has initiated a phase 2 clinical trial of the company's lead therapeutic compound, talabostat (PT-100), for treatment of advanced metastatic melanoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
5











